window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 18, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Series B funding

  • Biotech,Central Nervous System,Clinical Development,Clinical Trials,Pharmaceuticals and therapeutics,Rare Diseases

    Exciva raises €51 million Series B to fund phase 2 Alzheimer’s agitation trial

    Exciva GmbH has raised €51 million ($59m) in a Series [...]

    January 20, 2026
  • Artificial Intelligence,Biotech,Clinical Development,Diagnostics,Digital Health,Drug Development,Global health,Healthcare leadership,Precision medicine,Women's Health

    Clairity raises $43 million to launch FDA-authorized AI platform for breast cancer risk prediction

    Clairity, an AI-driven precision health company, has raised $43 million [...]

    November 13, 2025
  • Chronic diseases,Drug Development,European biotech,Pharmaceuticals and therapeutics

    MRM Health raises €55 million to advance microbiome-based therapies for ulcerative colitis and beyond

    MRM Health, a clinical stage biopharmaceutical company developing microbiome-based therapeutics, [...]

    September 9, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy
    Categories: Clinical Development, Clinical Trials, Digital Health, Funding, Mental health, Neurosciences, Pharmaceuticals and therapeutics
  • Kainova Therapeutics doses first patient in Europe in phase 1/2 anti-CCR8 antibody trial
    Categories: Clinical Trials, Oncology
  • START appoints Salwan Al Mutar to lead clinical research in Dallas-Fort Worth
    Categories: Clinical Development, Clinical Trials, Healthcare leadership, Oncology
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top